Skip to content

Study · Randomized controlled trial · n = 22 · 2024

5 results

Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.

Dietsche KB, Magge SN, Dixon SA, Davis FS, Krenek A, Chowdhury A, Mabundo L, Stagliano M, Courville AB, Yang S, Turner S, Cai H and 15 more

Show all authors

Kasturi K, Sherman AS, Ha J, Shouppe E, Walter M, Walter PJ, Chen KY, Brychta RJ, Peer C, Zeng Y, Figg W, Cogen F, Estrada DE, Chacko S, Chung ST

The Journal of clinical endocrinology and metabolism1 Apr 2024Cited by 13 (Europe PMC)

PMID37967247 (opens in a new tab)PMCIDPMC11031226 (opens in a new tab)DOI10.1210/clinem/dgad669 (opens in a new tab)PepBankPUB-37967247
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In youth with type 2 diabetes, metformin plus liraglutide decreased fasting glucose more than metformin alone.

    In plain wordsIn young people with type 2 diabetes, adding liraglutide to metformin lowered fasting glucose more than metformin alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseChange in fasting glucose
    Study

    n = 22

    Comparator
    Metformin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Change in fasting glucose
    −2 mmol/L
    Met + Lira
    Change in fasting glucose
    −0.6 mmol/L
    Met

    Source sentences

    Summary
    Met + Lira had a greater decrease from baseline in fasting glucose (-2.0 ± 1.3 vs -0.6 ± 0.9 mmol/L, P = .008)
    1 context sentence
    Summary · context
    In this parallel randomized clinical trial, 22 youth with Y-T2D-age 15.3 ± 2.1 years (mean ± SD), 68% female, body mass index (BMI) 40.1 ± 7.9 kg/m2, duration of diagnosis 1.8 ± 1.3 years-were randomized to metformin alone (Met) or metformin + liraglutide (Lira) (Met + Lira) and evaluated before and after 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In youth with type 2 diabetes, metformin plus liraglutide increased beta-cell function (sigma) more than metformin alone.

    In plain wordsIn young people with type 2 diabetes, adding liraglutide to metformin improved beta-cell function more than metformin alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseChange in beta-cell function (sigma)
    Study

    n = 22

    Comparator
    Metformin alone
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Change in sigma
    0.72
    Met + Lira
    Change in sigma
    −0.05
    Met

    Source sentences

    Summary
    and a greater increase in sigma (0.72 ± 0.68 vs -0.05 ± 0.71, P = .03)
    1 context sentence
    Summary · context
    In this parallel randomized clinical trial, 22 youth with Y-T2D-age 15.3 ± 2.1 years (mean ± SD), 68% female, body mass index (BMI) 40.1 ± 7.9 kg/m2, duration of diagnosis 1.8 ± 1.3 years-were randomized to metformin alone (Met) or metformin + liraglutide (Lira) (Met + Lira) and evaluated before and after 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In youth with type 2 diabetes, the change in fractional gluconeogenesis was similar with metformin plus liraglutide and metformin alone.

    In plain wordsIn young people with type 2 diabetes, adding liraglutide to metformin did not change sugar production by the liver more than metformin alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeChange in fractional gluconeogenesis
    Study

    n = 22

    Comparator
    Metformin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Change in fractional gluconeogenesis
    −0.36%
    Met + Lira
    Change in fractional gluconeogenesis
    0.04%
    Met

    Source sentences

    Summary
    The change in fractional gluconeogenesis was similar between groups (Met + Lira: -0.36 ± 9.4 vs Met: 0.04 ± 12.3%, P = .9)
    1 context sentence
    Summary · context
    In this parallel randomized clinical trial, 22 youth with Y-T2D-age 15.3 ± 2.1 years (mean ± SD), 68% female, body mass index (BMI) 40.1 ± 7.9 kg/m2, duration of diagnosis 1.8 ± 1.3 years-were randomized to metformin alone (Met) or metformin + liraglutide (Lira) (Met + Lira) and evaluated before and after 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In youth with type 2 diabetes, there were no changes in prandial gluconeogenesis.

    In plain wordsIn young people with type 2 diabetes, there were no changes in sugar production by the liver after meals.

    Peptide
    Liraglutide
    Outcome
    No significant changePrandial gluconeogenesis
    Study

    n = 22

    Comparator
    Metformin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    and there were no changes in prandial gluconeogenesis or mSI
    1 context sentence
    Summary · context
    In this parallel randomized clinical trial, 22 youth with Y-T2D-age 15.3 ± 2.1 years (mean ± SD), 68% female, body mass index (BMI) 40.1 ± 7.9 kg/m2, duration of diagnosis 1.8 ± 1.3 years-were randomized to metformin alone (Met) or metformin + liraglutide (Lira) (Met + Lira) and evaluated before and after 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In youth with type 2 diabetes, there were no changes in whole-body insulin sensitivity (mSI).

    In plain wordsIn young people with type 2 diabetes, there were no changes in whole-body insulin sensitivity.

    Peptide
    Liraglutide
    Outcome
    No significant changeWhole-body insulin sensitivity (mSI)
    Study

    n = 22

    Comparator
    Metformin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    and there were no changes in prandial gluconeogenesis or mSI
    1 context sentence
    Summary · context
    In this parallel randomized clinical trial, 22 youth with Y-T2D-age 15.3 ± 2.1 years (mean ± SD), 68% female, body mass index (BMI) 40.1 ± 7.9 kg/m2, duration of diagnosis 1.8 ± 1.3 years-were randomized to metformin alone (Met) or metformin + liraglutide (Lira) (Met + Lira) and evaluated before and after 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.